News
TAK
13.88
+0.07%
0.01
Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation
Seeking Alpha · 2d ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Seeking Alpha · 4d ago
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update
Dow Jones · 4d ago
Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines
Dow Jones · 4d ago
Weekly Report: what happened at TAK last week (0331-0404)?
Weekly Report · 6d ago
Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)
Seeking Alpha · 04/03 15:25
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
Benzinga · 04/02 19:29
Takeda upgraded to Overweight from Equal Weight at Morgan Stanley
TipRanks · 04/02 09:10
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns
Seeking Alpha · 04/01 18:27
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
NASDAQ · 03/31 15:40
Weekly Report: what happened at TAK last week (0324-0328)?
Weekly Report · 03/31 09:19
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Benzinga · 03/27 19:04
Takeda Canada says Health Canada expands marketing authorization for HyQvia
TipRanks · 03/27 13:41
Takeda's HyQvia Receives Expanded Market Authorization From Health Canada
Benzinga · 03/27 13:32
TAKEDA'S HYQVIA® RECEIVES EXPANDED MARKET AUTHORIZATION AS MAINTENANCE THERAPY FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
Reuters · 03/27 13:31
Mirum Pharmaceuticals partner Takeda receives approval for Livmarli in Japan
TipRanks · 03/27 13:11
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
NASDAQ · 03/24 19:00
Harmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakeda
TipRanks · 03/24 12:26
Weekly Report: what happened at TAK last week (0317-0321)?
Weekly Report · 03/24 09:17
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Benzinga · 03/21 16:31
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
More
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.